, Columnist
China's Revenue-Free Drug Trip
Chinese biotech companies are getting a euphoric welcome from global investors.
This article is for subscribers only.
Chinese companies listed in the U.S. have been bedeviled by corporate governance concerns and a string of accounting scandals.
So one might think that a new breed of companies that often have zero revenue and valuations based on no more than a tale of future promise would be a hard sell. Not so.